Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-target

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Maj

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runw

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Tran

Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its

BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical

Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including

Beam Therapeutics develops precision genetic medicines using base editing technology to target serio

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C.,

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and p

Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine compa

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechn

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechn

Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Con

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analys

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose

Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ: BEAM) in

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc (NASDAQ:ONDS) is losing a lot of mo

Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Tre

Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and rais

Beam Therapeutics shares rise after BEAM-302 trial data show sustained AAT levels above threshold, s

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patient

Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kob

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and

Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform an

Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly resu

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analys

Canaccord Genuity analyst Whitney Ijem initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updat

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 An

UBS analyst Michael Yee initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Neutral rati

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Sh

Evercore ISI Group analyst Cory Kasimov initiates coverage on Beam Therapeutics (NASDAQ:BEAM) wit